

Sara Pusceddu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4835758/sara-pusceddu-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

1,119
citations

18
h-index

30
g-index

75
ext. papers

1,406
ext. citations

4
avg. IF

3.9
L-index

#	Paper	IF	Citations
71	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. <i>Frontiers in Oncology</i> , 2022 , 12, 780716	5.3	1
70	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
69	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021 , 22, 161-169	4.9	3
68	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 628324	5.3	0
67	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. <i>Neuroendocrinology</i> , 2021 , 111, 475-489	5.6	9
66	NETs of the Lung 2021 , 163-178		0
65	Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?. <i>Oncologist</i> , 2020 , 25, e1257-e1258	5.7	1
64	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 156-164	3.8	12
63	Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups. <i>Cancers</i> , 2020 , 12,	6.6	5
62	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
61	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820927271	4.7	3
60	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. <i>Neuroendocrinology</i> , 2020 , 110, 616-629	5.6	22
59	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
58	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1111-1117	2.4	1
57	Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019 , 5, 217-226	5.3	16
56	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2019 , 134, 211-219	5.3	24
55	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	45

54	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , 2019 , 15, 3015-3024	3.6	0
53	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , 2019 , 19, 1067-1073	3.8	7
52	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 902	5.3	5
51	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , 2019 , 72, 45-55	14.4	51
50	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019 , 144, 1704-1712	7.5	9
49	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. <i>Tumori</i> , 2019 , 105, 113-120	1.7	4
48	The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. <i>Targeted Oncology</i> , 2018 , 13, 333-351	5	9
47	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 123, 57-73	7	26
46	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018 , 18, 198-203	3.8	14
45	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018 , 155, 479-489.e7	13.3	36
44	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. <i>Tumori</i> , 2018 , 104, 88-95	1.7	11
43	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018 , 25, 607-618	5.7	13
42	Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. <i>Neuroendocrinology</i> , 2018 , 106, 307-311	5.6	13
41	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018 , 13, 567-582	5	11
40	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , 2018 , 60, 490-498	4	41
39	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. <i>Neuroendocrinology</i> , 2017 , 104, 85-93	5.6	137
38	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1209-1224	4.9	8
37	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017 , 13, 1677-1683	3.6	4

36	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017 , 6, 1493-1499	4.8	9
35	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 183-188	5.4	17
34	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , 2017 , 57, 512-517	4	6
33	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 380-387	3.6	35
32	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 969-76	3.5	4
31	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016 , 37, 12991-13003	2.9	12
30	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016 , 37, 7047-57	2.9	34
29	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016 , 7, 44841-44847	3.3	9
28	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016 , 9, 432-439	1	2
27	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 167-76	7	26
26	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016 , 12, 1251-60	3.6	19
25	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , 2015 , 11, 1947-59	3.6	9
24	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2015 , 30, 429-30	3	1
23	Everolimus treatment in advanced solid tumors: a personal view. <i>Future Science OA</i> , 2015 , 1, FSO3	2.7	1
22	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. <i>Cancer</i> , 2014 , 120, 2457-63	6.4	52
21	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014 , 10, 1611-7	3.6	8
20	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , 2014 , 19, 966-74	5.7	66
19	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. <i>Annals of Oncology</i> , 2014 , 25, 1597-603	10.3	45

18	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. <i>Tumori</i> , 2014 , 100, e2-e3	1.7	6
17	Everolimus in advanced solid tumors: when to start, early or late?. <i>Tumori</i> , 2014 , 100, e2-3	1.7	3
16	Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. <i>Tumori</i> , 2014 , 100, e286-9	1.7	13
15	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. <i>Annals of Oncology</i> , 2013 , 24, 1415-6	10.3	2
14	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , 2013 , 99, e148-51	1.7	4
13	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4136-4136	2.2	2
12	Update on Therapeutic Strategy in Lung Carcinoids. <i>Journal of Cancer Therapy</i> , 2013 , 04, 1466-1471	0.2	1
11	A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 185-95	7	56
10	Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. <i>Tumori</i> , 2012 , 98, 394-394	1.7	4
9	Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. <i>Cancers</i> , 2012 , 4, 808-20	6.6	4
8	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2011 , 6, 181-6	5	7
7	Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?. <i>Tumori</i> , 2011 , 97, 564-7	1.7	14
6	Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. <i>Oncology Research</i> , 2011 , 19, 403-6	4.8	3
5	Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. <i>Tumori</i> , 2009 , 95, 501-507	1.7	3
4	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , 2009 , 3, 79-87	4.3	3
3	Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report. <i>International Journal of Gynecological Pathology</i> , 2008 , 27, 596-600	3.2	17
2	Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. <i>Oncology</i> , 2007 , 73, 204-9	3.6	27
1	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2007 , 18, 1810-6	10.3	28

